68
Participants
Start Date
May 1, 2024
Primary Completion Date
June 30, 2026
Study Completion Date
December 31, 2026
apatinib mesylate+Capecitabine Tablets
"Apatinib Mesylate Tablets: 500 mg, qd, orally until disease progression or intolerable adverse reactions.~Capecitabine Tablets: 1000 mg/m2, po, twice a day, d1-d14, discontinued for 1 week after 2 weeks of treatment;"
apatinib mesylate+Fulvestrant injection
"Apatinib Mesylate Tablets: 500 mg, qd, orally until disease progression or intolerable adverse reactions.~Fulvestrant injection 500 mg, intramuscular injection, q4w, once on d1 and d15 in the first cycle;"
Li Huiping
OTHER